Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the
4 hours ago
- #Triple-Negative Breast Cancer
- #First-Line Therapy
- #Antibody-Drug Conjugate
- The phase Ib/II BEGONIA study assessed datopotamab deruxtecan (Dato-DXd) combined with durvalumab as first-line therapy for unresectable locally advanced or metastatic triple-negative breast cancer.
- Arm 7 included patients regardless of PD-L1 expression; Arm 8 enrolled patients with PD-L1-high tumors. Dato-DXd 6 mg/kg plus durvalumab 1120 mg was administered intravenously every three weeks.
- In Arm 7 (62 patients, median follow-up 35.0 months), confirmed objective response rate was 79.0%, median duration of response was 17.6 months, and median progression-free survival was 14.0 months.
- In Arm 8 (33 patients, median follow-up 10.7 months), confirmed objective response rate was 81.8%, while median duration of response and progression-free survival were immature due to shorter follow-up.
- The safety profile of the combination was manageable with no new safety signals, demonstrating substantial and durable antitumor activity regardless of PD-L1 status.